Martin Murphy

Martin Murphy

Chief Executive Officer

Martin is Chief Executive Officer of Syncona Investment Management Ltd. He co-founded Syncona in 2012 alongside The Wellcome Trust.

Since then, Martin has been closely involved in the foundation and development of seven Syncona companies, including: Achilles Therapeutics, Autolus, OMass Therapeutics, Quell Therapeutics, Anaveon, Resolution Therapeutics and Clade Therapeutics. He is Chairman of Quell and Anaveon and is a Director of Autolus, Resolution, Neogene Therapeutics and Clade Therapeutics. He was previously Chairman of Blue Earth Diagnostics, which Syncona sold to Bracco Imaging for $476 million in 2019.

Previously, he was a partner at MVM Life Science Partners LLP, a venture capital company focused on life science and healthcare, where he led their European operations. Martin has also held roles with 3i Group plc and McKinsey & Company. He has a PhD in Biochemistry from the University of Cambridge.

Syncona portfolio companies

  • Anaveon (Chair)
  • Autolus (Board member)
  • Neogene Therapeutics (Board member)
  • Achilles Therapeutics
  • Quell Therapeutics (Chair)
  • OMass Therapeutics (Board observer )
  • Resolution Therapeutics (Board member)
  • Clade Therapeutics (Board member)
Chris Hollowood

Chris Hollowood

Chief Investment Officer
Markus John

Markus John

Chief Medical Officer and Head of R&D
Edward Hodgkin

Edward Hodgkin

Senior Partner
Elisa Petris

Elisa Petris

Lead Partner
Magdalena Jonikas

Magdalena Jonikas

Lead Partner
Alex Hamilton

Alex Hamilton

Investment Partner
Michael Kyriakides

Michael Kyriakides

Investment Partner
Gonzalo Garcia

Gonzalo Garcia

Investment Partner
Alice Renard

Alice Renard

Investment Partner
Raghd Rostom

Raghd Rostom

Associate Partner
Lisa Bright

Lisa Bright

Commercial Advisor
Ben Woolven

Ben Woolven

Business Strategy and Operations Partner